Financial PositionThe licensing agreement includes upfront and milestone payments that could total up to €191.5M, providing significant financial resources for Nicox.
Licensing AgreementA major licensing agreement with Kowa Company grants exclusive rights to develop and commercialize NCX 470 in the U.S. and other territories, potentially boosting Nicox's market presence.
Market PotentialThe global glaucoma market is approximately $7B, with the U.S. market accounting for roughly 40%, indicating significant market potential for NCX 470.